Effect of Non-essential Amino Acids on Protein Requirements for Endurance Athletes

NCT ID: NCT02874638

Last Updated: 2019-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Protein requirements in individuals who participate in endurance-based exercise training have been suggested to be greater than the current recommended dietary allowance (RDA).

The biological value of protein depends on its amino acid composition. Essential amino acids are believed to have main role on whole body protein metabolism. However, it remains to be determined what role non-essential amino acids (NEAA) may have in regulating protein metabolism and contributing to the increased protein requirements after endurance exercise.

The indicator amino acid oxidation (IAAO) method has clarified the individual amino acid requirement in children, normal healthy adult and clinical populations. However, the IAAO method has never been utilized for assessing the effect of NEAA on protein requirements after endurance exercise.

The objective of the current study is to investigate the importance of NEAA for endurance-trained male subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Increased Metabolic Requirement Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BASE egg protein

0.8 g/kg/d of BASE protein provided as crystalline amino acid made after egg protein.

Group Type EXPERIMENTAL

BASE egg protein

Intervention Type DIETARY_SUPPLEMENT

0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

BCAA-enriched egg protein

branched-chain amino acid-enriched egg protein

Group Type EXPERIMENTAL

BCAA-enriched egg protein

Intervention Type DIETARY_SUPPLEMENT

BCAA-enriched egg protein provided as crystalline amino acid.

small amount of essential amino acids

small amount of essential amino acids made after egg protein, which is equivalent to the amount of essential amino acids in BASE

Group Type EXPERIMENTAL

small amount of essential amino acids

Intervention Type DIETARY_SUPPLEMENT

essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein

large amount of essential amino acids

large amount of essential amino acids made after egg protein, which is equivalent to the amount of amino acids in BCAA

Group Type EXPERIMENTAL

large amount of essential amino acids

Intervention Type DIETARY_SUPPLEMENT

essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BASE egg protein

0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Intervention Type DIETARY_SUPPLEMENT

BCAA-enriched egg protein

BCAA-enriched egg protein provided as crystalline amino acid.

Intervention Type DIETARY_SUPPLEMENT

small amount of essential amino acids

essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein

Intervention Type DIETARY_SUPPLEMENT

large amount of essential amino acids

essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* endurance-trained participants who regularly run more than 40 km/week
* Participants who are categorized at least "very good" based on a study by Shvartz \& Reibold, in which VO2peak is used as an index. (i.e. the participants whose VO2peak is ≥57 ml/kg/min (18-24 y), ≥54 ml/kg/min (25-29 y), ≥52 ml/kg/min (30-34 y), ≥49 ml/kg/min (35-39 y)
* Ability to complete the 16-km familiarization run in session 2

Exclusion Criteria

* Inability to meet health and physical activity guidelines according to the physical activity readiness questionnaire (PAR-Q+)
* Inability to adhere to any of the protocol guidelines (i.e. alcohol, caffeine consumption)
* Regular tobacco use
* Illicit drug use
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ajinomoto Co., Inc.

INDUSTRY

Sponsor Role collaborator

University of Toronto

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daniel Moore

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel Moore, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Toronto

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IAAO-EA3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.